Munich Reinsurance Co Stock Corp in Munich Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Munich Reinsurance Co Stock Corp in Munich boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 412.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 316,534 shares of the biopharmaceutical company’s stock after buying an additional 254,813 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Bristol Myers Squibb were worth $19,198,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Northwestern Mutual Investment Management Company LLC grew its stake in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after acquiring an additional 172 shares in the last quarter. KCM Investment Advisors LLC lifted its position in shares of Bristol Myers Squibb by 0.8% during the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 174 shares in the last quarter. Investment Research Partners LLC boosted its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 179 shares during the last quarter. ESG Planning DBA Harper Investing grew its position in Bristol Myers Squibb by 1.3% in the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after purchasing an additional 180 shares in the last quarter. Finally, REAP Financial Group LLC increased its stake in Bristol Myers Squibb by 26.1% in the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 182 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on BMY. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. HSBC increased their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Trading Down 0.7%

Shares of BMY opened at $57.58 on Thursday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The business has a 50-day moving average of $56.84 and a 200 day moving average of $57.59. The firm has a market cap of $117.58 billion, a P/E ratio of 16.17, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.